Clive Mason | Programme Director, AMR
LifeArc

Clive Mason, Programme Director, AMR, LifeArc

Dr Clive Mason joined LifeArc in August 2023 to take on the role of Programme Director, AMR in the Global Health Team. Clive is also the LifeArc lead within the recently announced AMR-focused initiative called ‘PACE’ (Pathways to Antimicrobial Clinical Efficacy, https://paceamr.org.uk/ ). PACE was established to fund and support early innovative therapeutic and diagnostic approaches to meet the challenge of AMR.  Clive also supports other AMR-focused and Global Health initiatives within LifeArc. Clive has 25 years’ experience in biotechnology and drug discovery across a range of therapeutic areas. His most recent role was as VP, Anti-Infectives Research at Summit Therapeutics following their acquisition of Discuva Ltd (of which Clive was a founder). Discuva Ltd was established to develop and deploy a proprietary technology to enable the discovery and development of novel, new mechanism antimicrobials to address rising resistance to established classes of antibiotics. Through these roles Clive has contributed to the progression of a number of innovative antimicrobial agents; including a clinical stage asset, Ridinilazole (a novel DNA-minor groove binder) as a selective agent to treat and reduce recurrence of CDI, and SMT-738, a novel lipoprotein transport (lolCDE) inhibitor targeting Enterobacteriaceae.  Through his work Clive has developed a passion for finding solutions to meet the threat posed by AMR. He is an advocate for policy change to incentivise the discovery and development of AMR products and was previously a board member of the BEAM Alliance (https://beam-alliance.eu/). Clive obtained his Ph.D in Biological Sciences from the University of Warwick, UK.

Appearances:



Day 1 - World Antimicrobial Resistance Congress & Disease Prevention Control Summit 2024 @ 11:15

Chair Person

Day 1 - World Antimicrobial Resistance Congress & Disease Prevention Control Summit 2024 @ 12:00

Panel: Navigating the landscape - Strategies for early-stage developmental funding

The panel will address current strategies for early-stage funding chosen by the different panelists and give examples of successful company founding and funding. It will also address gaps and issues with the current funding landscape and within and between the supporting partners, and finally on novel business strategies chosen by the panelists to cope with those gaps. The addressed audience are start-ups, scientists and business developers in the AMR field and those planning to build a start-up, organizations supporting start-ups and everyone interested in early-stage development in the field of AMR.

 

 

 

Sponsored by LifeArc

last published: 14/Nov/24 16:45 GMT
last published: 14/Nov/24 16:45 GMT

back to speakers